Milestone Pharmaceuticals Inc. (MIST)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Milestone Pharmaceuticals Q1 Earnings Call Highlights
Milestone Pharmaceuticals NASDAQ: MIST said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular tachycardia, or PSVT, while the company also moved ahead with a Phase 3 program in atrial fibrillation with rapid ventricular rate.
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of $0.06. This compares to a loss of $0.31 per share a year ago.
Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript
Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense
Milestone Pharmaceuticals Inc. receives a Strong Buy rating, driven by Cardamyst's FDA approval and imminent commercial launch for PSVT. MIST's Cardamyst demonstrated rapid efficacy, favorable safety, and potential to reduce costly emergency visits, supporting robust market adoption. With over $150 million in cash, minimal near-term dilution risk, and nearly $1 net cash per share, MIST offers a highly asymmetric risk-reward.
Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript
Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution
Despite the CRL setback and heavy dilution, we remain optimistic on etripamil's long-term market potential and Milestone's investment thesis. The recent $52.5 million equity raise was poorly timed and dilutive, but it ensures Milestone's survival even if approval is delayed. Our updated financial model reflects higher risk, dilution, and a later launch, reducing risk-adjusted fair value but still offering upside.
Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst
I rate Milestone Pharmaceuticals Inc. a Strong Buy under $2, expecting FDA approval for Cardamyst in early 2026 after addressing recent regulatory setbacks. Cardamyst offers a unique, self-administered treatment for PSVT and AFib-RVR with no direct at-home competitors, strong efficacy, and significant pricing power. Financially, Milestone has sufficient runway into 2026, with a $75M milestone payment pending approval, though another small equity raise may be needed if they experience further delays.
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Milestone Pharmaceuticals (MIST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst
Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues.
US FDA declines to approve Milestone Pharma's heart rhythm nasal spray
The U.S. Food and Drug Administration has declined to approve Milestone Pharmaceuticals' nasal spray to treat a type of heart condition, the company said on Friday.
